Ludvik Bernhard, Brath Helmut, Wascher Thomas, Toplak Hermann
Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Wien, Austria.
Wien Klin Wochenschr. 2009;121(13-14):473-82. doi: 10.1007/s00508-009-1209-4.
Between 5 and 10% of the European population suffers from diabetes, and its prevalence is constantly rising, in Austria like in other countries. The main goals in the treatment of diabetes mellitus are the prevention of complications and organ damage, the prevention of severe hypo- and hyperglycaemia and the preservation of quality of life. Many patients with type 2 diabetes become insulin-dependent in the course of their disease. The application of a long acting insulin or insulin analogue is the simplest way of initiating an insulin therapy and is in accordance with current guidelines. Current scientific evidence shows that the use of long acting insulin analogues for type 2 diabetes; which can no longer be sufficiently controlled with oral antidiabetic agents, is simple, safe and efficacious. Thus, this treatment option should be available without any restrictions to physicians and patients in order to facilitate the beginning of an insulin regime. This position paper summarises up the current evidence concerning this subject.
在欧洲,5%至10%的人口患有糖尿病,而且其患病率在不断上升,奥地利和其他国家一样。糖尿病治疗的主要目标是预防并发症和器官损害,预防严重低血糖和高血糖,并维持生活质量。许多2型糖尿病患者在病程中会依赖胰岛素。应用长效胰岛素或胰岛素类似物是启动胰岛素治疗的最简单方法,并且符合当前指南。目前的科学证据表明,对于口服降糖药无法充分控制的2型糖尿病患者,使用长效胰岛素类似物简单、安全且有效。因此,为了便于开始胰岛素治疗方案,这种治疗选择应毫无限制地提供给医生和患者。本立场文件总结了关于该主题的当前证据。